Cargando…

Scientific Advancements in Drug Development and Trials for Urothelial Carcinoma: Insights From the 2023 ASCO-GU Cancers Symposium

Detalles Bibliográficos
Autores principales:	Feng, Dechao, Li, Dengxiong, Wu, Ruicheng, Han, Ping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	JKL International LLC 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676780/ https://www.ncbi.nlm.nih.gov/pubmed/37199595 http://dx.doi.org/10.14336/AD.2023.0502

Ejemplares similares

Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium
por: Yu, Jiazheng, et al.
Publicado: (2023)

Novel agents and clinical trials in castration-resistant prostate cancer: latest updates from 2023 ASCO-GU Cancers Symposium
por: Jiang, Yuanhong, et al.
Publicado: (2023)

Neues aus der Urologie von GU-ASCO, ASCO und EAU
por: Schnabel, Marco J., et al.
Publicado: (2020)

Hodentumoren: neue Erkenntnisse von ASCO-GU, ASCO und EAU 2021
por: Schrader, Mark
Publicado: (2021)

Highlights of ASCO 2023
por: Neugut, Alfred I, et al.
Publicado: (2023)

Recent Advances in Gynecological Malignancies: Focus on ASCO 2023
por: Bodriagova, Olga, et al.
Publicado: (2023)

Genitourinary cancers updates: highlights from ASCO 2023
por: Qin, Qian, et al.
Publicado: (2023)

ASCO20 Virtual Scientific Program: Takeaways for the Advanced Practitioner
por: Faiman, Beth
Publicado: (2020)

ASCO 2018: highlights of urothelial cancer and prostate cancer
por: Pichler, Renate, et al.
Publicado: (2018)

Abstracts from the 2023 SNO/ASCO CNS Cancer Conference
Publicado: (2023)

Practice change in the management of metastatic urothelial carcinoma after ASCO 2020
por: Gajate, Pablo, et al.
Publicado: (2020)

Melanoma: ASCO20 Virtual Scientific Program Highlights for the Advanced Practitioner
Publicado: (2020)

Gastrointestinal Cancers: ASCO20 Virtual Scientific Program Highlights for the Advanced Practitioner
Publicado: (2020)

Issues in Oncology: ASCO20 Virtual Scientific Program Highlights for the Advanced Practitioner
Publicado: (2020)

Prostate Cancer: ASCO20 Virtual Scientific Program Highlights for the Advanced Practitioner
Publicado: (2020)

Gynecologic Cancers: ASCO20 Virtual Scientific Program Highlights for the Advanced Practitioner
Publicado: (2020)

Thoracic Cancers: ASCO20 Virtual Scientific Program Highlights for the Advanced Practitioner
Publicado: (2020)

Hematologic Malignancies: ASCO20 Virtual Scientific Program Highlights for the Advanced Practitioner
Publicado: (2020)

Breast Cancer: ASCO20 Virtual Scientific Program Highlights for the Advanced Practitioner
Publicado: (2020)

ESMO/ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2023
por: Cufer, Tanja, et al.
Publicado: (2023)

Other Solid Cancers: ASCO20 Virtual Scientific Program Highlights for the Advanced Practitioner
Publicado: (2020)

Update on hepatocellular carcinoma from the 2018 Gastrointestinal Cancer Symposium (ASCO GI)
por: de Jesus, Victor Hugo Fonseca, et al.
Publicado: (2018)

Senescence-associated secretory phenotype constructed detrimental and beneficial subtypes and prognostic index for prostate cancer patients undergoing radical prostatectomy
por: Feng, Dechao, et al.
Publicado: (2023)

Genitourinary (Non-Prostate) Cancers: ASCO20 Virtual Scientific Program Highlights for the Advanced Practitioner
Publicado: (2020)

New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting
por: Roulleaux-Dugage, Matthieu, et al.
Publicado: (2023)

Large population-based study of upper tract urothelial carcinoma in China may provide further insight into the impact of bladder cancer on upper tract urothelial carcinoma’s prognosis in Chinese population
por: Zeng, Shuxiong, et al.
Publicado: (2022)

Prolyl 4-hydroxylase subunit beta (P4HB) could serve as a prognostic and radiosensitivity biomarker for prostate cancer patients
por: Feng, Dechao, et al.
Publicado: (2023)

Comparison of the FDA and ASCO/CAP Criteria for HER2 Immunohistochemistry in Upper Urinary Tract Urothelial Carcinoma
por: Kim, Gilhyang, et al.
Publicado: (2016)

Targeted Inhibition of P4HB Promotes Cell Sensitivity to Gemcitabine in Urothelial Carcinoma of the Bladder
por: Wang, Xiaoming, et al.
Publicado: (2020)

Erdafitinib for locally advanced or metastatic urothelial carcinoma
por: Siefker-Radtke, Arlene O, et al.
Publicado: (2022)

Prognostic value of COL10A1 and its correlation with tumor-infiltrating immune cells in urothelial bladder cancer: A comprehensive study based on bioinformatics and clinical analysis validation
por: Wang, Xiaoming, et al.
Publicado: (2023)

Symposium Mammographicum 2023
Publicado: (2023)

Identification of senescence-related lncRNA prognostic index correlating with prognosis and radiosensitivity in prostate cancer patients
por: Feng, Dechao, et al.
Publicado: (2023)

Female urethral diverticulum containing a urothelial carcinoma
por: Queiroz, Rodolfo Mendes, et al.
Publicado: (2016)

Prediction of survival in patients with upper tract urothelial carcinoma
por: Guo, Boda, et al.
Publicado: (2021)

2019 ASCO Annual Meeting: Takeaways for Advanced Practitioners
por: Viale, Pamela Hallquist
Publicado: (2019)

2021 ASCO Annual Meeting: Takeaways for the Advanced Practitioner
por: Faiman, Beth
Publicado: (2021)

2022 ASCO Annual Meeting: Takeaways for the Advanced Practitioner
por: Faiman, Beth
Publicado: (2022)

Analysis of conventional versus advanced pelvic floor muscle training in the management of urinary incontinence after radical prostatectomy: a systematic review and meta-analysis of randomized controlled trials
por: Feng, Dechao, et al.
Publicado: (2020)

ASCO update on lymphoma
por: Fridrik, Michael A.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_0216leh8e6q7u5t93coo387ntc